{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:36:45Z","timestamp":1789177005156,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eclinm.2025.103402","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T02:39:03Z","timestamp":1754966343000},"page":"103402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Safety of budesonide\/glycopyrronium\/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-254X","authenticated-orcid":false,"given":"Omar S.","family":"Usmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-3182","authenticated-orcid":false,"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Camiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Bednarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Kucz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Kokot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Gottfridsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Aurivillius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Skansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Petullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Collison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Bondarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Jassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103402_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1208\/s12249-013-0063-x","article-title":"Advances in metered dose inhaler technology: formulation development","volume":"15","author":"Myrdal","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.eclinm.2025.103402_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/17476348.2014.905916","article-title":"Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence","volume":"8","author":"Aggarwal","year":"2014","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.eclinm.2025.103402_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(18)30497-1","article-title":"Our planet or our patients \u2013 is the sky the limit for inhaler choice?","volume":"7","author":"Usmani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2025.103402_bib5","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.2147\/DDDT.S262141","article-title":"The climate is changing for metered-dose inhalers and action is needed","volume":"14","author":"Pritchard","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.eclinm.2025.103402_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02106-2021","article-title":"The environmental impact of inhaled therapy: making informed treatment choices","volume":"60","author":"Woodcock","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eclinm.2025.103402_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102245","article-title":"Relative bioavailability of budesonide\/glycopyrrolate\/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential","volume":"83","author":"Aurivillius","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2025.103402_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211034329","article-title":"Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial","volume":"15","author":"Rabe","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.eclinm.2025.103402_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2025.103402_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103402_bib12","first-page":"A38","article-title":"A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines [abstract S60]","volume":"77","author":"Hargreaves","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.eclinm.2025.103402_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/10915818231206025","article-title":"The nonclinical assessment of trans-1,3,3,3-tetrafluoropropene (HFO-1234ze (E)), a near zero global warming potential propellant for use in metered dose inhalation products","volume":"43","author":"Giffen","year":"2024","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.eclinm.2025.103402_bib15","article-title":"Systemic exposure bioequivalence of budesonide\/glycopyrrolate\/formoterol fumarate with the potential next generation propellant hydrofluoroolefin-1234ze versus hydrofluoroalkane-134a in healthy adults [abstract]","volume":"209","author":"Shah","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eclinm.2025.103402_bib16","article-title":"Lung exposure bioequivalence with budesonide\/glycopyrrolate\/formoterol fumarate with the next generation propellant hydrofluoroolefin-1234ze versus hydrofluoroalkane-134a in healthy adults: a charcoal block study [abstract]","volume":"209","author":"Raphiou","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eclinm.2025.103402_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eclinm.2025.103402_bib18","first-page":"434","article-title":"The diagnosis and treatment of COPD and its comorbidities","volume":"120","author":"Kahnert","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.eclinm.2025.103402_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/15412555.2012.744963","article-title":"Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001\u20132008","volume":"10","author":"Putcha","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.eclinm.2025.103402_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/15412555.2012.761960","article-title":"Inhaler devices for patients with COPD","volume":"10","author":"Fink","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.eclinm.2025.103402_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:23:03Z","timestamp":1772914983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":18,"alternative-id":["S2589537025003347"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103402","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of budesonide\/glycopyrronium\/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103402"}}